# A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma

> **NCT03514407** · PHASE1 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 25 (actual)

## Conditions studied

- Relapsed Ewing Sarcoma

## Interventions

- **DRUG:** INCB059872

## Key facts

- **NCT ID:** NCT03514407
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-27
- **Primary completion:** 2020-06-25
- **Final completion:** 2020-06-25
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Strategic Business Decision
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03514407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03514407, "A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03514407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*